
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc is advancing its gene therapy portfolio with a focus on significant revenue growth tied to its TRACER platform, particularly from collaborations that are progressing into clinical trials expected in the 2030s. Preclinical results demonstrate considerable efficacy, with VY1706 achieving up to a 73% reduction in tau messenger RNA and over a 50% reduction in tau protein in non-human primates, indicating strong therapeutic potential with durable effects. Additionally, the company's innovative NeuroShuttle platform showcases enhanced central nervous system exposure and safety advantages, reinforcing Voyager's position in the gene therapy market for severe neurological diseases.
Bears say
The financial performance of Voyager Therapeutics indicates significant challenges, including a high burn rate and limited revenue generation, which raises concerns about the company's ability to sustain its operations and fund ongoing research and development. Moreover, the reliance on a narrow pipeline of gene therapies, particularly in a competitive and rapidly evolving field, presents risks related to clinical trial outcomes and market acceptance. Additionally, delays in trial progress and potential regulatory hurdles could further impact the company's ability to commercialize its therapies and achieve financial stability in the near term.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares